Showing results (451-460 of 485) with videos related to
Sort By:
Pageof 49
Blood Advances|December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implicationNikolaus Jahn, Tobias Terzer, Eric Sträng, et al.Haematologica|April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapyMarie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.Annals of Hematology|October 4, 2016
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyRichard F Schlenk, Michael Lübbert, Axel Benner, et al.Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.Transplantation and Cellular Therapy|December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk GroupNikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.Transplantation and Cellular Therapy|September 2, 2021
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host DiseaseMakda Getachew Zewde, George Morales, Isha Gandhi, et al.Pageof 49